ECSP11011219A - Nuevas formas polimórficas de dihidrógeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparación. - Google Patents

Nuevas formas polimórficas de dihidrógeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparación.

Info

Publication number
ECSP11011219A
ECSP11011219A EC2011011219A ECSP11011219A ECSP11011219A EC SP11011219 A ECSP11011219 A EC SP11011219A EC 2011011219 A EC2011011219 A EC 2011011219A EC SP11011219 A ECSP11011219 A EC SP11011219A EC SP11011219 A ECSP11011219 A EC SP11011219A
Authority
EC
Ecuador
Prior art keywords
methyl
processes
dihydrogen
phosphate
polymodic
Prior art date
Application number
EC2011011219A
Other languages
English (en)
Inventor
Dieter Dorsch
Christoph Saal
Frank Stieber
Axel Becker
Clemens Kuehn
Eva Kriegbaum
Cristina Donini
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41609799&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011219(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP11011219A publication Critical patent/ECSP11011219A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a dihidrógeno-fosfato de 6-(1-metil-1H-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2H-piridazin-3-ona, sus solvatos y modificaciones cristalinas. La presente invención también se refiere a procesos de preparación de estas modificaciones cristalinas, así como a su uso en el tratamiento y/o la prevención de condiciones fisiológicas y/o patofisiológicas que son causadas, mediadas y/o propagadas por la inhibición, regulación y/o modulación de la transducción de señales de quinasas, en particular por la inhibición de tirosina quinasas, por ejemplo, condiciones patofisiológicas como el cáncer.
EC2011011219A 2008-12-22 2011-07-21 Nuevas formas polimórficas de dihidrógeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparación. ECSP11011219A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08022253 2008-12-22

Publications (1)

Publication Number Publication Date
ECSP11011219A true ECSP11011219A (es) 2011-12-30

Family

ID=41609799

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011219A ECSP11011219A (es) 2008-12-22 2011-07-21 Nuevas formas polimórficas de dihidrógeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparación.

Country Status (32)

Country Link
US (1) US8586599B2 (es)
EP (1) EP2361250B1 (es)
JP (2) JP5690741B2 (es)
KR (1) KR101663335B1 (es)
CN (1) CN102264729B (es)
AR (1) AR074686A1 (es)
AU (1) AU2009331990B2 (es)
BR (1) BRPI0923480B8 (es)
CA (1) CA2748218C (es)
CL (1) CL2011001278A1 (es)
CO (1) CO6331435A2 (es)
CY (1) CY1114659T1 (es)
DK (1) DK2361250T3 (es)
EA (1) EA019320B1 (es)
EC (1) ECSP11011219A (es)
ES (1) ES2434247T3 (es)
HK (1) HK1164837A1 (es)
HR (1) HRP20130993T1 (es)
IL (1) IL213647A (es)
MX (1) MX2011006682A (es)
MY (1) MY160526A (es)
NZ (1) NZ594172A (es)
PE (1) PE20120016A1 (es)
PL (1) PL2361250T3 (es)
PT (1) PT2361250E (es)
SG (1) SG172128A1 (es)
SI (1) SI2361250T1 (es)
SM (1) SMT201300133B (es)
TW (1) TWI448463B (es)
UA (1) UA103646C2 (es)
WO (1) WO2010072295A1 (es)
ZA (1) ZA201105394B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
KR20180092096A (ko) 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
ES2946551T3 (es) 2017-10-17 2023-07-20 Palau Pharma S L U Síntesis de compuestos de 4-aminopirimidina

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19604388A1 (de) 1996-02-07 1997-08-14 Merck Patent Gmbh Arylalkyl-diazinone
JPH10259176A (ja) 1997-03-17 1998-09-29 Japan Tobacco Inc 血管新生阻害作用を有する新規アミド誘導体及びその用途
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
AUPQ462299A0 (en) 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
US6242461B1 (en) 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
JP2005515975A (ja) 2001-10-31 2005-06-02 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング ４型ホスホジエステラーゼ阻害剤およびこれらの使用
JP2006514043A (ja) 2002-12-20 2006-04-27 ファルマシア・コーポレーション マイトジェン活性化タンパク質キナーゼ−活性化タンパク質キナーゼ−２を阻害する化合物
EP1643836A4 (en) 2003-07-02 2006-12-06 Sugen Inc ARYLMETHYL TRIAZOLO AND IMIDAZOPYRAZINE C-MET INHIBITORS
US7959919B2 (en) 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
US20070015771A1 (en) 2004-07-29 2007-01-18 Threshold Pharmaceuticals, Inc. Lonidamine analogs
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
WO2006015263A2 (en) 2004-07-29 2006-02-09 Threshold Pharmaceuticals, Inc. Lonidamine analogs
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
CA2630884A1 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
DE102005057924A1 (de) 2005-12-05 2007-06-06 Merck Patent Gmbh Pyridazinonderivate
EA015754B1 (ru) 2005-12-21 2011-12-30 Янссен Фармацевтика, Н.В. Триазолопиридазины в качестве модуляторов тирозинкиназы
WO2007130383A2 (en) 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
PE20091079A1 (es) 2007-10-16 2009-08-24 Novartis Ag Compuestos heterociclicos como moduladores npy y2
AU2008315746A1 (en) 2007-10-25 2009-04-30 Astrazeneca Ab Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
CN101842359A (zh) 2007-10-31 2010-09-22 日产化学工业株式会社 哒嗪酮化合物和p2x7受体抑制剂
WO2009063061A2 (en) 2007-11-16 2009-05-22 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
CL2008003799A1 (es) 2007-12-21 2009-12-18 Synthon Bv Composicion farmaceutica que comprende raloxifeno en forma de tableta de liberacion inmediata; util para el tratamiento y/o prevencion de la osteoporosis.
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
CL2008003785A1 (es) 2007-12-21 2009-10-09 Du Pont Compuestos derivados de piridazina; composiciones herbicidas que comprenden a dichos compuestos; y método para controlar el crecimiento de la vegetación indeseada.
GB0725059D0 (en) 2007-12-21 2008-01-30 Syngenta Participations Ag Novel pyridazine derivatives
TW200930375A (en) 2007-12-21 2009-07-16 Exelixis Inc Benzofuropyrimidinones
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
KR101204213B1 (ko) 2007-12-21 2012-11-26 에프. 호프만-라 로슈 아게 오렉신 수용체 길항제로서의 헤테로아릴 유도체
AU2008339572B2 (en) 2007-12-21 2012-05-10 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
EP2072506A1 (de) 2007-12-21 2009-06-24 Bayer CropScience AG Thiazolyloxyphenylamidine oder Thiadiazolyloxyphenylamidine und deren Verwendung als Fungizide
MX2010006397A (es) 2007-12-21 2010-07-05 Hoffmann La Roche Compuestos heterociclicos antivirales.
CL2008003811A1 (es) 2007-12-21 2009-05-22 Palau Pharma Sa Compuestos derivados de 4-aminopirimidina-2,6-disustituidos, antagonistas del receptor de histamina h4; proceso de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad alergica, inmunologica o inflamatoria, o dolor.
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
US7816540B2 (en) 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
CN101537006B (zh) 2008-03-18 2012-06-06 中国科学院上海药物研究所 哒嗪酮类化合物在制备抗肿瘤药物中的用途
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
CN102105454A (zh) 2008-07-25 2011-06-22 贝林格尔.英格海姆国际有限公司 合成1型11β-羟基类固醇脱氢酶的抑制剂
US20120028988A1 (en) 2009-03-30 2012-02-02 Sumitomo Chemical Company, Limited Use of pyridazinone compound for control of harmful arthropod pests
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton

Also Published As

Publication number Publication date
ZA201105394B (en) 2012-03-28
CL2011001278A1 (es) 2011-09-30
TWI448463B (zh) 2014-08-11
IL213647A0 (en) 2011-07-31
CA2748218A1 (en) 2010-07-01
MX2011006682A (es) 2011-07-13
JP2012513417A (ja) 2012-06-14
EP2361250B1 (en) 2013-08-07
CO6331435A2 (es) 2011-10-20
SI2361250T1 (sl) 2013-12-31
SG172128A1 (en) 2011-07-28
JP2015028093A (ja) 2015-02-12
US8586599B2 (en) 2013-11-19
CA2748218C (en) 2017-08-29
EP2361250A1 (en) 2011-08-31
NZ594172A (en) 2013-04-26
JP5690741B2 (ja) 2015-03-25
IL213647A (en) 2013-11-28
CN102264729B (zh) 2014-03-05
TW201028409A (en) 2010-08-01
EA019320B1 (ru) 2014-02-28
UA103646C2 (ru) 2013-11-11
PL2361250T3 (pl) 2014-01-31
AU2009331990B2 (en) 2016-04-14
ES2434247T3 (es) 2013-12-16
CN102264729A (zh) 2011-11-30
MY160526A (en) 2017-03-15
AU2009331990A1 (en) 2011-08-11
CY1114659T1 (el) 2016-10-05
AR074686A1 (es) 2011-02-02
US20110257180A1 (en) 2011-10-20
JP5860125B2 (ja) 2016-02-16
BRPI0923480B8 (pt) 2021-05-25
PE20120016A1 (es) 2012-01-24
SMT201300133B (it) 2014-03-07
KR101663335B1 (ko) 2016-10-06
BRPI0923480B1 (pt) 2020-10-13
EA201100973A1 (ru) 2012-01-30
HRP20130993T1 (hr) 2013-11-22
DK2361250T3 (da) 2013-11-04
KR20110089462A (ko) 2011-08-08
PT2361250E (pt) 2013-11-11
WO2010072295A1 (en) 2010-07-01
BRPI0923480A2 (pt) 2016-08-09
HK1164837A1 (en) 2012-09-28

Similar Documents

Publication Publication Date Title
ECSP11011248A (es) Nuevas formas polimórficas de sal de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo y sus procesos de preparación.
CO6612243A2 (es) Derivados de [1.8]naftiridina
ECSP11011534A (es) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- o heptano-nitrilo como inhibidores de jak
CU24187B1 (es) Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis
CR20130280A (es) Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
CL2012003503A1 (es) Compuestos derivados de morfolin pirimidinas sustituidos, inhibidores de la proteina quinasa atr; composicion farmaceutica, utiles para la prevencion o el tratamiento de tumores cancerigenos.
MX353308B (es) Derivados fosforosos como inhibidores de cinasa.
DK3808749T3 (da) Pyrazolo[1,5-a]pyrimidiner, der er nyttige som inhibitorer af atr-kinase til behandling af kræftsygdomme
AU2011276193A8 (en) Bipyridyl derivatives useful for the treatment of kinase - induced diseases
UY33587A (es) Nuevos compuestos como inhibidores de quinasas syk y jak
ECSP10010263A (es) 4-pirazolil-n-arilpirimidin-2-aminas y 4-pirazolil-n-heteroarilpirimidin-2-aminas como inhibidores de cinasas janus
HN2010001761A (es) Derivados de azetidina y ciclobutano como inhibidores de jak
GT201300046A (es) Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3)
MX2014010849A (es) Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico.
MX2011012369A (es) Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa.
CL2011001972A1 (es) Compuestos derivados de pirimidina fusionada, inhibidores akt; proceso de preparacion de dichos compuestos y compuestos intermediarios; compuestos intermediarios; composicion farmaceutica que los comprende; combinacion farmaceutica que los comprende y sus usos en el tratamiento de enfermedades hiperproliferativas.
ECSP11011219A (es) Nuevas formas polimórficas de dihidrógeno-fosfato de 6-(1-metil-1h-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2h-piridazin-3-ona y procesos para su preparación.
WO2010062848A8 (en) Substituted pyrazole compounds
CL2009001112A1 (es) Compuestos derivados de cinolin-3-carboxamida, inhibidores de la quinasa csf-1r; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
BRPI0912970A2 (pt) derivados de di-hidropirazol como moduladores de tirosina quinase para o tratamento de tumores
TH135036B (th) รูปแบบโพลีมอร์ฟิคใหม่ของ 6-(1-เมทธิล-1h-ไพราโซล-4-อิล)-2-{3-[5-(2-มอร์โฟลีน -4-อิล-เอทธอกซี)-ไพริมิดีน-2-อิล]-เบนซิล}-2h-ไพริดาซีน-3-โอน ไดไฮโดรเจนฟอสเฟต และกระบวนการผลิตผลึกดังกล่าว
TH135036A (th) รูปแบบโพลีมอร์ฟิคใหม่ของ 6-(1-เมทธิล-1h-ไพราโซล-4-อิล)-2-{3-[5-(2-มอร์โฟลีน-4-อิล-เอทธอกซี)-ไพริมิดีน-2-อิล]-เบนซิล}-2h-ไพริดาซีน-3-โอน ไดไฮโดรเจนฟอสเฟต และกระบวนการผลิตผลึกดังกล่าว
NZ743260A (en) Bipiperidine-2-one compounds for the preparation of pyrimidinyl tyrosine kinase inhibitors
UY33553A (es) Heteroarilos y usos de los mismos